QA: Monopar Therapeutics in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001645469_2023_Monopar_Therapeutics.pdf

Logs

info Added remainder_ComprehensiveNetIncome directly from 10K industry.us_generic {}

Graph

Absolute values for 0001645469, Monopar Therapeutics

  xvar xval
0 AssetsCurrent 13,165,726
1 IntangibleAssetsNetIncludingGoodwill 0
2 PropertyPlantAndEquipmentNet 0
3 remainder_Assets 61,228
4 LiabilitiesCurrent 3,128,894
5 LiabilitiesNoncurrent 8,408
6 remainder_Liabilities 0
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 2,945,276
9 ResearchAndDevelopmentExpense 7,591,601
10 remainder_Expenses 0
11 remainder_Revenues 0
12 remainder_NetIncome 21,239
13 remainder_ComprehensiveNetIncome 12,102
  yvar yval
0 Assets 13,226,954
1 Liabilities 3,137,302
2 Expenses 10,536,877
3 Revenues 0
4 StockholdersEquity 10,089,652
5 NetIncome -10,515,638
6 ComprehensiveNetIncome -10,509,587
7 BaseVar 13,467,237
8 EconomicCapitalRatio 0.837

Edgar->Model Mapping

Feature Distribution

Change over Time